Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia—Review and Expert Opinion
Open accessThe DOI matches its Crossref record; 91 of the 92 references it cites were found in a registry or an index.
Abstract
Cancer cachexia is a multilayered syndrome consisting of the interaction between tumor cells and the host, at times modulated by the pharmacologic treatments used for tumor control. Key cellular and soluble mediators, activated because of this interaction, induce metabolic and nutritional alterations. This results in mass and functional changes systemically, and can lead to increased morbidity and reduced length and quality of life. For most solid malignancies, a cure remains an unrealistic goal, and targeting the key mediators is ineffective because of their heterogeneity/redundancy. The most beneficial approach is to target underlying systemic mechanisms, an approach where the novel non-peptide ghrelin analogue anamorelin has the advantage of stimulating appetite and possibly food intake, as well as promoting anabolism and significant muscle mass gain. In the ROMANA studies, compared with placebo, anamorelin significantly increased lean body mass in non-small cell lung cancer (NSCLC) patients. Body composition analysis suggested that anamorelin is an active anabolic agent in patients with NSCLC, without the side effects of other anabolic drugs. Anamorelin also induced a significant and meaningful improvement of anorexia/cachexia symptoms. The ROMANA trials have provided unprecedented knowledge, highlighting the therapeutic effects of anamorelin as an initial, but significant, step toward directly managing cancer cachexia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This oral ghrelin analogue has mostly been studied in cancer217–219 and has anti-inflammatory and anabolic properties.”
From Sarcopenic obesity in older adults: a clinical overview (2024) · cites this paper as [217]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Garber, C. E., Blissmer, B., Deschenes, M. R., Franklin, B. A., Lamonte, M. J., Lee, I.-M., Nieman, D. C., & Swain, D. P. (2011) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e318213fefb · Cited by 9,319
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020 · cited 5×
“The Functional Assessment of Cancer Therapy-General (FACT-G) [90] is the core instrument, and contains four domains: physical, functional, emotional, and social well-being.”
InfluentialSelf-citationDefinition and classification of cancer cachexia: an international consensus
Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L., Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70218-7 · Cited by 5,767 · cited 4×
“This threshold was chosen on the basis of the consideration that an unintended weight loss of ≥5% represents one of the diagnostic criteria for cancer anorexia/cachexia [1].”
BackgroundInfluentialSelf-citationESPEN guidelines on nutrition in cancer patients
Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Fearon, K., Hütterer, E., Isenring, E., Kaasa, S., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.07.015 · Cited by 3,114 · cited 5×
“Across multiple cohort studies, patients with low LBM experience more severe or dose-limiting toxicities and earlier cessation of chemotherapy compared with those with relatively higher LBM [22].”
BackgroundInfluentialSelf-citationMartin, L., Birdsell, L., MacDonald, N., Reiman, T., Clandinin, M. T., McCargar, L. J., Murphy, R., Ghosh, S., Sawyer, M. B., & Baracos, V. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2722 · Cited by 2,680 · cited 1×
“Patients with severe weight loss are an at-risk population [44] that is extremely difficult to treat [45].”
BackgroundMourtzakis, M., Prado, C. M. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-075 · Cited by 2,224 · cited 1×
“An assessment approach that considers body composition is important for patients with lung cancer and cachexia, as neither body weight [46,47] nor BMI [48] are strongly correlated with LBM or skeletal muscle.”
BackgroundMuscaritoli, M., Anker, S. D., Argilés, J., Aversa, Z., Bauer, J. M., Biolo, G., Boirie, Y., Bosaeus, I., Cederholm, T., Costelli, P., et al. (2010) · Clinical Nutrition · doi:10.1016/j.clnu.2009.12.004 · Cited by 1,732 · cited 1×
“The FAACT questionnaire contains the 12-item A/CS domain that specifically addresses anorexia/cachexia (Table 2), and is the ideal tool to measure the complex phenomenon of appetite/eating [92], as the questions not only evaluate cancer anorexia/cachexia symptoms and concerns including appetite, early satiety, and oth…”
MethodSelf-citationESPEN expert group recommendations for action against cancer-related malnutrition
Arends, J., Baracos, V., Bertz, H., Bozzetti, F., Calder, P. C., Deutz, N. E. P., Erickson, N., Laviano, A., Lisanti, M. P., Lobo, D. N., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2017.06.017 · Cited by 1,305 · cited 1×
“The etiology of cancer cachexia is not yet fully clarified; central features comprise anorexia, reduced food intake, and increased systemic inflammation (C-reactive protein levels above upper limits of normal) [2,3].”
BackgroundSelf-citationAge-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases
Kalyani, R. R., Corriere, M., & Ferrucci, L. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70034-8 · Cited by 1,102 · cited 1×
“A decline in LBM is observed as a natural feature of aging, with LBM reported to decrease from 50% of total body weight in healthy young adults to about 25% by the age of 75–80 years [49,50].”
BackgroundPrevalence of Malnutrition and Current Use of Nutrition Support in Patients With Cancer
Hébuterne, X., Lemarié, E., Michallet, M., de Montreuil, C. B., Schneider, S. M., & Goldwasser, F. (2014) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607113502674 · Cited by 823 · cited 1×
“By definition, nutritional therapy alone cannot reverse the effects of cancer cachexia [22,78].”
BackgroundDiagnostic Criteria for the Classification of Cancer-Associated Weight Loss
Martin, L., Senesse, P., Gioulbasanis, I., Antoun, S., Bozzetti, F., Deans, C., Strasser, F., Thoresen, L., Jagoe, R. T., Chasen, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.1894 · Cited by 798 · cited 1×
“The more accentuated the weight loss and the more rapid the decrease in BMI, the stronger the correlation with higher morbidity and mortality [9].”
BackgroundFearon, K. C., Voss, A. C., & Hustead, D. S. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1345 · Cited by 779
Temel, J. S., Abernethy, A. P., Currow, D. C., Friend, J., Duus, E. M., Yan, Y., & Fearon, K. C. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00558-6 · Cited by 639
Self-citationLean Tissue Imaging: A New Era for Nutritional Assessment and Intervention
Prado, C. M. M., & Heymsfield, S. B. (2014) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607114550189 · Cited by 550
Baracos, V. E., Reiman, T., Mourtzakis, M., Gioulbasanis, I., & Antoun, S. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.28608c · Cited by 482 · cited 1×
“An assessment approach that considers body composition is important for patients with lung cancer and cachexia, as neither body weight [46,47] nor BMI [48] are strongly correlated with LBM or skeletal muscle.”
BackgroundAge and aerobic exercise training effects on whole body and muscle protein metabolism
Short, K. R., Vittone, J. L., Bigelow, M. L., Proctor, D. N., & Nair, K. S. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00366.2003 · Cited by 470 · cited 1×
“A decline in LBM is observed as a natural feature of aging, with LBM reported to decrease from 50% of total body weight in healthy young adults to about 25% by the age of 75–80 years [49,50].”
BackgroundMoses, A. W. G., Slater, C., Preston, T., Barber, M. D., & Fearon, K. C. H. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601620 · Cited by 452 · cited 1×
“The daily deficit in total energy expenditure of patients with advanced cancer is approximately 100–200 kcal per day [81].”
BackgroundCancer cachexia, mechanism and treatment
Aoyagi, T., Terracina, K. P., Raza, A., Matsubara, H., & Takabe, K. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i4.17 · Cited by 434
Antoun, S., Baracos, V. E., Birdsell, L., Escudier, B., & Sawyer, M. B. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp605 · Cited by 420 · cited 1×
“These findings are not limited to cancer type or anticancer drug, as low LBM is shown to predict toxicity in patients with various types of cancers treated with sorafenib [60], sunitinib [61], or afatinib [62].”
BackgroundBaldwin, C., Spiro, A., Ahern, R., & Emery, P. W. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr556 · Cited by 400 · cited 1×
“FM represents a central location for energy storage, and a diminished accumulation of fatty tissue cannot be reversed by nutritional intervention alone [79], indicating that patients with FM loss have a profoundly altered metabolism.”
BackgroundPrevalence, incidence and clinical impact of cachexia: facts and numbers—update 2014
von Haehling, S., & Anker, S. D. (2014) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-014-0164-8 · Cited by 395
Yennurajalingam, S., Frisbee-Hume, S., Palmer, J. L., Delgado-Guay, M. O., Bull, J., Phan, A. T., Tannir, N. M., Litton, J. K., Reddy, A., Hui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.4661 · Cited by 348
Solheim, T. S., Laird, B. J. A., Balstad, T. R., Stene, G. B., Bye, A., Johns, N., Pettersen, C. H., Fallon, M., Fayers, P., Fearon, K., et al. (2017) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12201 · Cited by 311 · cited 1×
“Guidelines suggest a multimodal approach to treating cancer cachexia that comprises nutritional intervention, physical exercise to support maintenance of function [28,29], and pharmacologic treatment, although very limited data concerning the efficacy of this proposed strategy are currently available [30].”
BackgroundAapro, M., Arends, J., Bozzetti, F., Fearon, K., Grunberg, S. M., Herrstedt, J., Hopkinson, J., Jacquelin-Ravel, N., Jatoi, A., Kaasa, S., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu085 · Cited by 308
Megestrol acetate for treatment of anorexia-cachexia syndrome
Ruiz Garcia, V., López-Briz, E., Carbonell Sanchis, R., Gonzalvez Perales, J. L., & Bort-Martí, S. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004310.pub3 · Cited by 293 · cited 1×
“For progestational agents, prolonged administration increases the risk of thromboembolic events [23,24], adrenal insufficiency [25], fluid retention, hypogonadism, and death [23].”
BackgroundCorticosteroid-induced clinical adverse events: frequency, risk factors and patient?s opinion
Fardet, L., Flahault, A., Kettaneh, A., Tiev, K. P., Généreau, T., Tolédano, C., Lebbé, C., & Cabane, J. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07950.x · Cited by 273 · cited 1×
“The most notable problem is that corticosteroids are catabolic and, as such, can contribute to skeletal muscle wasting [13,19,20].”
BackgroundCancer cachexia—pathophysiology and management
Suzuki, H., Asakawa, A., Amitani, H., Nakamura, N., & Inui, A. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0787-0 · Cited by 268
Lieffers, J. R., Mourtzakis, M., Hall, K. D., McCargar, L. J., Prado, C. M., & Baracos, V. E. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.27273 · Cited by 251 · cited 1×
“[83], who estimated the contributions of organ and tumor mass to whole-body energy demands by monitoring changes in body composition of patients with advanced colorectal cancer and cachexia.”
BackgroundHusson, O., de Rooij, B. H., Kieffer, J., Oerlemans, S., Mols, F., Aaronson, N. K., van der Graaf, W. T. A., & van de Poll-Franse, L. V. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0348 · Cited by 245
Muscle dysfunction in cancer patients
Christensen, J. F., Jones, L. W., Andersen, J. L., Daugaard, G., Rorth, M., & Hojman, P. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt551 · Cited by 242 · cited 1×
“Loss of LBM depletes this storage, diminishes physiologic reserves, and reduces the ability to withstand insult, particularly in response to stress [55,56].”
BackgroundCancer cachexia: impact, mechanisms and emerging treatments
Vaughan, V. C., Martin, P., & Lewandowski, P. A. (2013) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-012-0087-1 · Cited by 233
Yip, C., Dinkel, C., Mahajan, A., Siddique, M., Cook, G. J. R., & Goh, V. (2015) · Insights into Imaging · doi:10.1007/s13244-015-0414-0 · Cited by 230 · cited 1×
“An assessment approach that considers body composition is important for patients with lung cancer and cachexia, as neither body weight [46,47] nor BMI [48] are strongly correlated with LBM or skeletal muscle.”
BackgroundPrado, C. M., Sawyer, M. B., Ghosh, S., Lieffers, J. R., Esfandiari, N., Antoun, S., & Baracos, V. E. (2013) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.060228 · Cited by 228 · cited 3×
“In patients with cancer cachexia, nutritional therapy to satisfy protein and caloric needs is usually inadequate [54].”
BackgroundInfluentialHuillard, O., Mir, O., Peyromaure, M., Tlemsani, C., Giroux, J., Boudou-Rouquette, P., Ropert, S., Delongchamps, N. B., Zerbib, M., & Goldwasser, F. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.58 · Cited by 227 · cited 1×
“These findings are not limited to cancer type or anticancer drug, as low LBM is shown to predict toxicity in patients with various types of cancers treated with sorafenib [60], sunitinib [61], or afatinib [62].”
BackgroundRier, H. N., Jager, A., Sleijfer, S., Maier, A. B., & Levin, M.-D. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0066 · Cited by 226
Paulsen, Ø., Klepstad, P., Rosland, J. H., Aass, N., Albert, E., Fayers, P., & Kaasa, S. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3926 · Cited by 215
Cancer-induced muscle wasting: latest findings in prevention and treatment
Aversa, Z., Costelli, P., & Muscaritoli, M. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017698643 · Cited by 215 · cited 2×
“The most notable problem is that corticosteroids are catabolic and, as such, can contribute to skeletal muscle wasting [13,19,20].”
BackgroundSelf-citationChanges in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer
Stene, G. B., Helbostad, J. L., Amundsen, T., Sørhaug, S., Hjelde, H., Kaasa, S., & Grønberg, B. H. (2015) · Acta Oncologica · doi:10.3109/0284186x.2014.953259 · Cited by 210 · cited 1×
“Conversely, maintaining or gaining muscle mass during chemotherapy has been independently associated with reduced mortality, which may reflect stabilization of the disease, but also successful management of cancer cachexia [63].”
BackgroundRibaudo, J. M., Cella, D., Hahn, E. A., Lloyd, S. R., Tchekmedyian, N. S., Roenn, J. V., & Leslie, W. T. (2000) · Quality of Life Research · doi:10.1023/a:1016670403148 · Cited by 202 · cited 13×
“The international, randomized, double-blind, placebo-controlled phase 3 trials ROMANA 1 (NCT01387269) and ROMANA 2 (NCT01387282) assessed the efficacy and safety of anamorelin in patients with advanced NSCLC and cachexia over a 12-week period [38] (Table 1).”
BackgroundMethodInfluentialSelf-citationHigh-intensity training following lung cancer surgery: a randomised controlled trial
Edvardsen, E., Skjonsberg, O. H., Holme, I., Nordsletten, L., Borchsenius, F., & Anderssen, S. A. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-205944 · Cited by 182 · cited 1×
“20 kg per month [52], the 1 to 2 kg increase observed after the 12-week anamorelin treatment is clinically relevant, and similar to that reported for lung cancer patients recovering from resection surgery and following high-intensity exercise training [69].”
BackgroundStewart Coats, A. J., Ho, G. F., Prabhash, K., von Haehling, S., Tilson, J., Brown, R., Beadle, J., Anker, S. D., & for and on behalf of the ACT‐ONE study group (2016) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12126 · Cited by 179
Currow, D., Temel, J. S., Abernethy, A., Milanowski, J., Friend, J., & Fearon, K. C. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx192 · Cited by 179 · cited 1×
“Importantly, the reported improvements in symptom burden were consistently maintained throughout the 12-week safety extension study ROMANA 3 [41,95].”
BackgroundSelf-citationCrawford, J., Prado, C. M. M., Johnston, M. A., Gralla, R. J., Taylor, R. P., Hancock, M. L., & Dalton, J. T. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0522-0 · Cited by 178
Wallengren, O., Lundholm, K., & Bosaeus, I. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-012-1697-z · Cited by 177 · cited 1×
“Patients with advanced non-small cell lung cancer (NSCLC) and cachexia also present with respiratory complications that compound the symptom burden of cachexia, including debilitating fatigue [11].”
BackgroundAli, R., Baracos, V. E., Sawyer, M. B., Bianchi, L., Roberts, S., Assenat, E., Mollevi, C., & Senesse, P. (2016) · Cancer Medicine · doi:10.1002/cam4.621 · Cited by 177 · cited 2×
“Recent examples include cohorts of patients with newly diagnosed lung cancer (N = 134) [58], patients commencing first- or second-line chemotherapy (N = 200) [59], and patients scheduled for any anticancer treatment (N = 80) [57].”
BackgroundPrognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer
Kimura, M., Naito, T., Kenmotsu, H., Taira, T., Wakuda, K., Oyakawa, T., Hisamatsu, Y., Tokito, T., Imai, H., Akamatsu, H., et al. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-014-2534-3 · Cited by 175 · cited 2×
“Recent examples include cohorts of patients with newly diagnosed lung cancer (N = 134) [58], patients commencing first- or second-line chemotherapy (N = 200) [59], and patients scheduled for any anticancer treatment (N = 80) [57].”
BackgroundStrasser, F., Lutz, T. A., Maeder, M. T., Thuerlimann, B., Bueche, D., Tschöp, M., Kaufmann, K., Holst, B., Brändle, M., von Moos, R., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604148 · Cited by 160
Clinical evaluation and optimal management of cancer cachexia
Tuca, A., Jiménez‐Fonseca, P., & Gascón, P. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.07.015 · Cited by 126 · cited 2×
“Currently used drugs, such as corticosteroids and progestational agents, have been shown to enhance appetite and increase body weight [14–16], but have little, if any, positive effect on LBM and skeletal muscle [17,18].”
BackgroundNeural respiratory drive, pulmonary mechanics and breathlessness in patients with cystic fibrosis
Reilly, C. C., Ward, K., Jolley, C. J., Lunt, A. C., Steier, J., Elston, C., Polkey, M. I., Rafferty, G. F., & Moxham, J. (2011) · Thorax · doi:10.1136/thx.2010.142646 · Cited by 126 · cited 1×
“With impaired respiratory muscle capacity, the body cannot respond appropriately to these afferent messages, and the resultant efferent–afferent mismatch is responsible for chronic breathlessness [67,68].”
BackgroundNattenmüller, J., Wochner, R., Muley, T., Steins, M. B., Hummler, S., Teucher, B., Wiskemann, J., Kauczor, H., Wielpütz, M. O., & Heußel, C. P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169136 · Cited by 125 · cited 1×
“Recent examples include cohorts of patients with newly diagnosed lung cancer (N = 134) [58], patients commencing first- or second-line chemotherapy (N = 200) [59], and patients scheduled for any anticancer treatment (N = 80) [57].”
BackgroundPsychosocial impact of cancer cachexia
Hopkinson, J. B. (2014) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1007/s13539-014-0142-1 · Cited by 121
Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function
Stephens, N. A., Gray, C. D., MacDonald, A. J., Tan, B. H. L., Gallagher, I. J., Skipworth, R. J. E., Ross, J. A., Fearon, K. C. H., & Greig, C. A. (2012) · Clinical Nutrition · doi:10.1016/j.clnu.2011.12.008 · Cited by 113 · cited 1×
“This lack of significance may be explained, in part, by the continually worsening condition of these patients with advanced disease, the absence of a training program for these small muscles coupled with the volitional nature of testing that draws on neuromuscular performance, as well as the low mechanical quality of…”
BackgroundLundholm, K., Gunnebo, L., Körner, U., Iresjö, B., Engström, C., Hyltander, A., Smedh, U., & Bosaeus, I. (2010) · Cancer · doi:10.1002/cncr.24917 · Cited by 102
Exercise for cancer cachexia in adults
Grande, A. J., Silva, V., Riera, R., Medeiros, A., Vitoriano, S., Peccin, M. S., & Maddocks, M. M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010804.pub2 · Cited by 101 · cited 1×
“Guidelines suggest a multimodal approach to treating cancer cachexia that comprises nutritional intervention, physical exercise to support maintenance of function [28,29], and pharmacologic treatment, although very limited data concerning the efficacy of this proposed strategy are currently available [30].”
BackgroundSelf-citationMurphy, R. A., Mourtzakis, M., Chu, Q. S.-C., Reiman, T., & Mazurak, V. C. (2010) · Journal of Nutrition · doi:10.3945/jn.110.123521 · Cited by 100 · cited 1×
“20 kg per month [52] and, in patients with lung cancer, up to 6% over 100 days [53].”
BackgroundGrande, A. J., Silva, V., & Maddocks, M. (2015) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12055 · Cited by 97 · cited 2×
“These positive results were confirmed in a post hoc analysis performed in 829 patients from the ROMANA 1 and ROMANA 2 trials [71], where significant improvements in the A/CS domain score were observed over 12 weeks with anamorelin when compared with placebo (treatment difference: 1.”
BackgroundResultSelf-citationGhrelin: Ghrelin as a Regulatory Peptide in Growth Hormone Secretion
Khatib, N. (2014) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2014/9863.4767 · Cited by 97
The “parallel pathway”: a novel nutritional and metabolic approach to cancer patients
Muscaritoli, M., Molfino, A., Gioia, G., Laviano, A., & Fanelli, F. R. (2010) · Internal and Emergency Medicine · doi:10.1007/s11739-010-0426-1 · Cited by 96 · cited 2×
“The etiology of cancer cachexia is not yet fully clarified; central features comprise anorexia, reduced food intake, and increased systemic inflammation (C-reactive protein levels above upper limits of normal) [2,3].”
BackgroundSelf-citationArrieta, O. G., la Torre-Vallejo, M. D., López-Macías, D., Orta, D., Turcott, J. G., Macedo-Pérez, E. O., Sánchez-Lara, K., Ramírez-Tirado, L.-A., & Baracos, V. E. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0058 · Cited by 96 · cited 1×
“These findings are not limited to cancer type or anticancer drug, as low LBM is shown to predict toxicity in patients with various types of cancers treated with sorafenib [60], sunitinib [61], or afatinib [62].”
BackgroundLoss of muscle mass in the end of life in patients with advanced cancer
Wallengren, O., Iresjö, B., Lundholm, K., & Bosaeus, I. G. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2332-y · Cited by 95 · cited 2×
“20 kg per month [52] and, in patients with lung cancer, up to 6% over 100 days [53].”
BackgroundHasselgren, P.-O., Alamdari, N., Aversa, Z., Gonnella, P., Smith, I. J., & Tizio, S. (2010) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32833a5107 · Cited by 94 · cited 1×
“The most notable problem is that corticosteroids are catabolic and, as such, can contribute to skeletal muscle wasting [13,19,20].”
BackgroundBlauwhoff-Buskermolen, S., Ruijgrok, C., Ostelo, R. W., de Vet, H. C. W., Verheul, H. M. W., de van der Schueren, M. A. E., & Langius, J. A. E. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-015-2826-2 · Cited by 91 · cited 1×
“The FAACT assessment tool combines the FACT-G with the A/CS [39] and has been validated in patients with anorexia/cachexia and advanced cancers [91], including NSCLC [8,39].”
MethodCachexia: A preventable comorbidity of cancer. A T.A.R.G.E.T. approach
Muscaritoli, M., Molfino, A., Lucia, S., & Fanelli, F. R. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.10.014 · Cited by 87
Self-citationTreatment of dyspnoea in advanced cancer patients: ESMO Clinical Practice Guidelines
Kloke, M., & Cherny, N. I. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv306 · Cited by 85
Cancer cachexia: medical management
Mantovani, G., & Madeddu, C. (2009) · Supportive Care in Cancer · doi:10.1007/s00520-009-0722-3 · Cited by 81 · cited 1×
“For corticosteroids, the long-term adverse events (AEs) include insulin resistance, fluid retention, steroidal myopathy, skin fragility, adrenal insufficiency, immunosuppression, and psychotropic effects [21,22].”
BackgroundImportance of lean body mass in the oncologic patient.
Tsai, S. (2012) · Nutrition in clinical practice · doi:10.1177/0884533612457949 · Cited by 80 · cited 1×
“Loss of LBM depletes this storage, diminishes physiologic reserves, and reduces the ability to withstand insult, particularly in response to stress [55,56].”
BackgroundLeBlanc, T. W., Nipp, R. D., Rushing, C. N., Samsa, G., Locke, S. C., Kamal, A. H., Cella, D. F., & Abernethy, A. P. (2014) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2014.09.008 · Cited by 76 · cited 11×
“The international, randomized, double-blind, placebo-controlled phase 3 trials ROMANA 1 (NCT01387269) and ROMANA 2 (NCT01387282) assessed the efficacy and safety of anamorelin in patients with advanced NSCLC and cachexia over a 12-week period [38] (Table 1).”
BackgroundMethodInfluentialSelf-citationCachexia and Wasting: A Modern Approach
Mantovani, G., Yeh, S., Schuster, M. W., Scevola, D., Morley, J. E., Inui, A., Fanelli, F. R., & Anker, S. D. (2006) · Springer eBooks · doi:10.1007/978-88-470-0552-5 · Cited by 74
Garber, K. (2016) · Nature Biotechnology · doi:10.1038/nbt.3557 · Cited by 65
Medroxyprogesterone acetate in the management of cancer cachexia
Madeddu, C., Macciò, A., Panzone, F., Tanca, F. M., & Mantovani, G. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902960162 · Cited by 62
Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC
Zhang, H., & Garcia, J. M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1041500 · Cited by 60 · cited 1×
“Anamorelin is a novel, orally active, highly selective non-peptide ghrelin analogue that has been shown to simultaneously target multiple components of cancer cachexia, including appetite, body composition, adipose tissue metabolism, energy expenditure, and inflammation [36,37].”
BackgroundUpdate on Management of Cancer-Related Cachexia
Anderson, L. J., Albrecht, E. D., & Garcia, J. M. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0562-0 · Cited by 60 · cited 1×
“In the clinical setting, a noteworthy response to nutritional support is observed in patients with severe undernutrition (BMI <20 kg/m2 at baseline) [1,18,42].”
BackgroundDev, R., Del Fabbro, E., & Bruera, E. (2007) · Cancer · doi:10.1002/cncr.22924 · Cited by 55 · cited 1×
“Currently used drugs, such as corticosteroids and progestational agents, have been shown to enhance appetite and increase body weight [14–16], but have little, if any, positive effect on LBM and skeletal muscle [17,18].”
BackgroundTreating cancer cachexia to treat cancer
Lee, S.-J., & Glass, D. J. (2011) · Skeletal Muscle · doi:10.1186/2044-5040-1-2 · Cited by 50 · cited 1×
“, handgrip strength, sit-to-stand, stair-climbing power) are suitable surrogate measures of strength in patients with advanced cancer and cachexia still needs to be established [77].”
BackgroundManagement of Anorexia-Cachexia in Late-Stage Lung Cancer Patients
Ferraro, C. D., GRANT, M. M., Koczywas, M., & Dorr-Uyemura, L. A. (2012) · Journal of Hospice and Palliative Nursing · doi:10.1097/njh.0b013e31825f3470 · Cited by 45
Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review
Sever, S., White, D. L., & Garcia, J. M. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0130 · Cited by 45
Handgrip dynamometry, Cybex measurements and lean mass as markers of the ageing of muscle function.
Shephard, R. J., Montelpare, W., Plyley, M. J., McCracken, D., & Goode, R. C. (1991) · British Journal of Sports Medicine · doi:10.1136/bjsm.25.4.204 · Cited by 43
Anamorelin Hydrochloride in the Treatment of Cancer Anorexia-Cachexia Syndrome
Currow, D. C., & Abernethy, A. P. (2014) · Future Oncology · doi:10.2217/fon.14.14 · Cited by 42 · cited 1×
“Anamorelin is a novel, orally active, highly selective non-peptide ghrelin analogue that has been shown to simultaneously target multiple components of cancer cachexia, including appetite, body composition, adipose tissue metabolism, energy expenditure, and inflammation [36,37].”
BackgroundSelf-citationThe Role of Ghrelin in Anorexia–Cachexia Syndromes
Guillory, B., Splenser, A. E., & Garcia, J. M. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-410473-0.00003-9 · Cited by 39 · cited 1×
“Ghrelin, a peptide gastric hormone, is the endogenous ligand of the growth hormone (GH) secretagogue receptor 1a and stimulates multiple pathways that regulate appetite, LBM, body weight, and metabolism [31,32].”
BackgroundFactors influencing exercise performance in thoracic cancer
England, R., Maddocks, M. M., Manderson, C., & Wilcock, A. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2011.11.002 · Cited by 34
Self-citationDudgeon, D. J., & Baracos, V. E. (2016) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000222 · Cited by 29 · cited 1×
“These waste products also provide an afferent feedback to the respiratory centers to increase the rate of breathing [66].”
BackgroundErratum to: Update on Management of Cancer-Related Cachexia
Anderson, L. J., Albrecht, E. D., & Garcia, J. M. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0595-4 · Cited by 20
van der Meij, B. S., Phernambucq, E. C. J., Fieten, G. M., Smit, E. F., Paul, M. A., van Leeuwen, P. A. M., & Oosterhuis, J. W. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182208e90 · Cited by 19 · cited 1×
“Patients with severe weight loss are an at-risk population [44] that is extremely difficult to treat [45].”
BackgroundMegestrol acetate-induced adrenal insufficiency
Villarroel, P. G., Pérez, I. F., Páramo, C., González, M. G., López, B. C., Tuñas, M. L. V., & Álvarez, J. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0188-7 · Cited by 19
Targeting cancer cachexia: we're on the way
Muscaritoli, M. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00085-1 · Cited by 8
Self-citationCurrow, D. C., Temel, J. S., Fearon, K. C. H., Friend, J., Yan, Y., & Abernethy, A. P. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)30691-8 · Cited by 3
Self-citationRodríguez, A. M., Duus, E. M., & Friend, J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.26_suppl.71 · Cited by 3 · cited 1×
“A recent survey among 95 patients with advanced NSCLC compared QOL and anorexia/cachexia symptom burden in patients with and without considerable weight loss on survey initiation [93].”
BackgroundCurrow, D. C., Temel, J. S., Abernethy, A. P., Friend, J., & Giorgino, R. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.10097 · Cited by 3 · cited 1×
“3% of patients with BMI <20 kg/m2 at baseline benefited from anamorelin [43], compared with 13.”
BackgroundSelf-citationHusson, O., de Rooij, B. H., Kieffer, J. M., Oerlemans, S., Mols, F., Aaronson, N. K., van der Graaf, W. T. A., & van de Poll-Franse, L. V. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.10070 · Cited by 3 · cited 1×
“Hence, patient-reported measures, which can provide direct evidence of social and clinical outcomes [8] and have independent prognostic value [87], are necessary to assess items of relevance in patients with anorexia/cachexia [88].”
BackgroundWallis, C. J. D., Magee, D., Satkunasivam, R., & Nam, R. K. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.6_suppl.288 · Cited by 2
Currow, D. C., Temel, J. S., Giorgino, R., Abernethy, A. P., Friend, J., & Fearon, K. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.10119 · Cited by 1 · cited 1×
“In this large data set (N = 829), the increase in FM concurred with that reported for the individual trials [80].”
ResultSelf-citation
Research works printed but not linked: 4
- Currow D. Temel J. Abernethy A. Friend J. Giorgino R. Fearon K.C. Pooled efficacy data from ROMANA 1 and ROMANA 2, two phase 3 trials of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with cachexia Support. Care Cancer 2016 24 S23 PS006
- Crawford J.C. Johnston M.A. Hancock M.L. Small S.G. Taylor R.P. Dalton J.P. Steiner M.S. Enobosarm, a selective androgen receptor modulator (SARM), increases lean body mass (LBM) in advanced NSCLC patients; updated results of two pivotal, international Phase 3 trials Proceedings of the MASCC/ISOO International Symposium on Supportive Care in Cancer Miami, FL, USA 26–28 June 2014 MASCC-0546
- Cella D.F. Bonomi A.E. Leslie W.T. Von Roenn J. Tchekmedyian N.S. Quality of life and nutritional well-being: Measurement and relationship Oncology 1993 7 S105 S111
- Gelhorn H.L. Gries K.S. Duus E.M. Bourne R.K. Friend J.E. Speck R.M. Leidy N.K. Cella D. Psychometric properties of the FAACT Additional Concerns Subscale (A/CS) for measurement of anorexia in patients with non-small cell lung cancer Proceedings of the International Society for Quality of Life Research 23rd Annual Conference Copenhagen, Denmark 19–22 October 2016 Poster 1005
Cited by
Sarcopenic obesity in older adults: a clinical overview
Prado, C. M., Batsis, J. A., Donini, L. M., Gonzalez, M. C., & Siervo, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00943-z · Cited by 355
Cancer Cachexia: Definition, Staging, and Emerging Treatments
Ni, J., & Zhang, L. (2020) · Cancer Management and Research · doi:10.2147/cmar.s261585 · Cited by 290
Muscle Wasting and Sarcopenia in Heart Failure—The Current State of Science
Lena, A., Anker, M. S., & Springer, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186549 · Cited by 159
Osteosarcopenia: A Narrative Review on Clinical Studies
Polito, A., Barnaba, L., Ciarapica, D., & Azzini, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105591 · Cited by 136
“Ghrelin agonists can determine the improvement of malnutrition and increase muscle mass or strength [85].”
BackgroundZhu, X., Callahan, M. F., Gruber, K. A., Szumowski, M., & Marks, D. L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138392 · Cited by 60
“Some of these agents have found their way into clinical trials in patients with cachexia (32, 35, 36).”
Background
Metadata
- Authors
- Currow, D. C., Maddocks, M., Cella, D., & Muscaritoli, M.
- Affiliations
- University of Technology Sydney (AU)
- King's College London (GB)
- Northwestern University (US)
- Sapienza University of Rome (IT)
- Corresponding author
- Muscaritoli, Maurizio
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-11-05
- Volume
- 19
- Issue
- 11
- Pages
- 3471
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6275064
- OpenAlex
- W2900369002
- Cited by
- 27
- References
- 92
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 1 · 2022: 3 · 2021: 5 · 2020: 8 · 2019: 3
- FWCI
- 0.53
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UTS ePRESS (University of Technology Sydney) (submittedVersion)
- Funders
- Helsinn Healthcare SA (NA)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- anamorelin, cancer cachexia, non-small cell lung cancer, appetite stimulation, lean body mass, anabolic therapy, muscle mass gain, anorexia, body composition
- MeSH terms
- Body Weight, Cachexia, Carcinoma, Non-Small-Cell Lung, Humans, Hydrazines, Oligopeptides, Hand Strength, Ghrelin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

